1-(4,6-二甲氧嘧啶-2-基)-3-(2-乙基磺酰基咪唑[1,2-a]-3-吡啶基磺酰基)脲 | 141776-32-1

• 物质功能分类: 分析化学 - 标准品 - 农残、兽药及化肥类
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(4,6-二甲氧嘧啶-2-基)-3-(2-乙基磺酰基咪唑[1,2-a]-3-吡啶基磺酰基)脲
• 中文别名: N-[[(4,6-二甲氧基-2-嘧啶基)氨基]甲酰]-2-(乙基磺酰)咪唑并[1,2-a]吡啶-3-磺酰胺；磺酰磺隆；1-(4,6-二甲氧吡啶-2-基)-3-[(2-乙基磺酰基-咪唑[1,2-α]吡啶)磺酰基]脲；磺胺磺隆
• 英文名称: sulfosulfuron
• 英文别名: 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea；1-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-ylsulfonyl)-3-(4,6-dimethoxypyrimidin-2-yl)-urea
• CAS: 141776-32-1
• 化学式: C₁₆H₁₈N₆O₇S₂
• 分子量: 470.487
• InChiKey: RBSXHDIPCIWOMG-UHFFFAOYSA-N

物化性质

• 熔点：
  201.1-201.7°
• 密度：
  1.63±0.1 g/cm3(Predicted)
• 溶解度：
  Solubility in organic solvents (g/l at 20 °C) Acetone 0.71 Ethyl acetate 1.01 Dichloromethane 4.35 n‐Heptane <0.001 Methanol 0.33 Xylene 0.16
• LogP：
  3.040 (est)
• 颜色/状态：
  White crystals
• 气味：
  Odorless
• 蒸汽压力：
  6.61X10-10 mm Hg at 25 °C
• 稳定性/保质期：
  Stable <54 °C for 14 days. Hydrolysis DT50 7 days (pH 4), 48 days (pH 5), 168 days (pH 7), 156 days (pH 9) (all 25 °C).
• 解离常数：
  pKa = 3.51

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  188
• 氢给体数：
  2
• 氢受体数：
  10

ADMET

代谢

在代谢研究中，向斯普拉格-道利大鼠给药了放射性标记的磺磺隆（98%的放射化学纯有效成分）。在预实验中，每性别每组2-3只大鼠分别通过灌胃给药10毫克/千克或1000毫克/千克的(14)C-Pd磺磺隆（放射性标记在嘧啶环的C-5位置）或(14)C-Im磺磺隆（放射性标记在咪唑并吡啶环的C-3位置）。给予Im或Pd磺磺隆同位素的大鼠具有相似的代谢物轮廓；因此，在主要研究中，每性别每组5只大鼠给药了(14)C-Pd、(14)C-Im、(13)C-Im和(12)C-磺磺隆的混合物，单次口服剂量为10毫克/千克或1000毫克/千克，重复口服剂量为10毫克/千克（14个连续的日常未标记剂量，随后是一个放射性标记剂量），或者单次静脉注射剂量为10毫克/千克。... 所有组别中磺磺隆的代谢都很少，大部分以未代谢的形式排出（例如，在尿液中排出的总放射性中占比超过90%）。磺磺隆主要通过嘧啶环上碳原子的环羟基化或嘧啶环上4或6位置的甲氧基去甲基化进行代谢。此外，还观察到少量的磺酰胺键断裂生成磺酰胺或其他咪唑并吡啶化合物和嘧啶化合物。尿液中检测到的主要代谢物包括去甲基磺磺隆（占给药剂量的3.6%或更多）、5-羟基磺磺隆（1.9%或更多）和磺酰胺（2.6%或更多）。第四种代谢物，Feces 488（ND-1.68%，仅在粪便中），部分被鉴定为去甲基化代谢物。其他少量代谢物，1种咪唑并吡啶和3种嘧啶代谢物，在粪便中也被检测到，但水平较低（<1%）。不同剂量（高剂量与低剂量）、给药次数（单次与重复）、给药方式（口服与静脉注射）或性别（雄性与雌性）之间代谢物轮廓在质量上相似（不同代谢物的百分比有差异，但由于存在的水平较低，这些差异被认为在生物学上不显著）。注意到在高剂量大鼠给药后12小时和24小时的尿液中观察到了少量白色沉淀物。这些沉淀物未被表征，但基于低水平的生物转化，它们可能是未代谢的磺磺隆。

In a metabolism study, radiolabelled Sulfosulfuron (98% radiochemically pure a.i.), was administered to Sprague-Dawley rats. In the pilot study, 2-3 rats/sex/group were administered either (14)C-Pd Sulfosulfuron (radiolabel at the C-5 position of pyrimidine ring) or (14)C-Im Sulfosulfuron (label at the C-3 position of the imidazopyridine ring), each at 10 mg/kg or 1,000 mg/kg, by gavage. Rats dosed with Im or Pd Sulfosulfuron isotopes had similar metabolite profiles; therefore in the main study, 5 rats/sex/group were administered a mixture of (14)C-Pd, (14)C-Im, (13)C-Im and (12)C- Sulfosulfuron at single oral doses of 10 or 1,000 mg/kg, repeated oral doses of 10 mg/kg (14 consecutive daily unlabelled doses, followed by 1 radiolabelled dose), or a single intravenous dose of 10 mg/kg. ... Metabolism of Sulfosulfuron in all groups was minimal and most was excreted unmetabolized (for example, it represented more than 90% of the total radioactivity excreted in the urine). Sulfosulfuron was metabolized primarily via ring hydroxylation of a carbon of the pyrimidine ring, or demethylation of the methoxy group at the 4- or 6-position of the pyrimidine ring. In addition, a limited amount of cleavage of the sulfonamide bond into sulfonamide or other imidazopyridine compounds and pyrimidine compounds was observed. Major metabolites identified in urine and feces were desmethyl Sulfosulfuron (3.6% or greater of administered dose), 5-hydroxy Sulfosulfuron (1.9% or greater) and sulfonamide (2.6% or greater). A fourth, Feces 488 (ND-1.68%; feces only), was partially characterized as a desmethylated metabolite. Other minor metabolites, 1 imidazopyridine and 3 pyrimidine metabolites, were also found at low levels (<1%) in the feces. Metabolite profiles were qualitatively similar among animals given high vs. low doses, single vs. repeated doses, oral vs. intravenous doses, or between males and females (the percentages of different metabolites varied but due to the low levels present, variations were not considered biologically significant). It was noted that small amounts of white precipitates were observed in the urine of high dose rats at 12 and 24 hrs post-dosing. These were not characterized, but were probably unmetabolized Sulfosulfuron, based on the low level of biotransformation.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分的中和。如果患者停止呼吸，请开始人工呼吸，最好使用需求阀复苏器、球囊阀面罩设备或口袋面罩，按训练操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果患者呕吐，让患者向前倾或将其置于左侧（如果可能的话，头部向下），以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗救助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，协助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预期癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能够吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最小流量/。如果出现低血容量的迹象，使用0.9%的生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

/遗传毒性/ 在一项体外细胞遗传学分析中，从单一捐赠者获得的人淋巴细胞被暴露于磺磺隆。在初步实验（3小时暴露于磺磺隆，有或没有S9活化系统，随后进行17小时培养，然后2小时暴露于可可米德）和确认实验（-S9：19.5小时和43.4小时暴露于磺磺隆，随后使用可可米德；+S9：与初步实验相同）中，S9混合物来源于Aroclor 1254诱导的大鼠肝脏，测试材料以DMSO溶液的形式传递到测试系统。在所有实验和收获时间中评估的最高剂量水平（有或没有S9）为1000微克/毫升。在这个剂量水平上观察到沉淀。此外，在这个剂量水平上有或没有S9时，有丝分裂指数的降低（从14.9%到66.7%）。然而，没有迹象表明有任何细胞染色体畸变和/或多倍体细胞数量的增加。阳性对照诱发了预期的高产量含有染色体畸变的 metaphase spreads。基于这些考虑，可以得出结论，磺磺隆在本实验条件下，在有或没有S9的情况下，直至包括那些与细胞毒性和/或测试材料沉淀相关的剂量，均未在人淋巴细胞中诱导出裂解反应。

/GENOTOXICITY/ In an in vitro cytogenetic assay, cultured human lymphocytes, obtained from a single donor, were exposed to Sulfosulfuron in initial (3-hr exposure with and without S9 to Sulfosulfuron, followed by 17-hr incubation and then 2-hr exposure to colcemid) and confirmatory (-S9: 19.5- and 43.4-hr exposures to Sulfosulfuron, followed by colcemid; +S9: same as initial) assays. The S9 homogenate was derived from Aroclor 1254-induced rat livers and the test material was delivered to the test system as a solution in DMSO. The highest dose level evaluated (with and without S9) in all assays and harvest times was 1000 ug/mL. A precipitate was observed at this dose level. In addition, reductions (from 14.9 to 66.7%) were seen in mitotic indices at this dose level with and without S9. However, there were no indications of any increased incidence of cells with chromosomal aberrations and/or numbers of polyploid cells. The positive controls induced the expected high yields of metaphase spreads with chromosomal aberrations. Based on the these considerations, it is concluded that Sulfosulfuron did not induce a clastogenic response in human lymphocytes under the conditions of this assay either in the presence or absence of S9 at doses up to and including those associated with cytotoxicity and/or test material precipitation.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

实验室动物：亚慢性或前慢性暴露/ 在一项亚慢性毒性研究中，将Sulfosulfuron（98.4% a.i.）通过明胶胶囊给予50只比格犬（每组5只雄性/5只雌性），剂量水平为（0、30、100、300和1,000 mg/kg/天），持续90天。对照组接受空明胶胶囊。Sulfosulfuron的毒性效应主要表现在泌尿道，似乎是300和1000 mg/kg/天剂量下形成尿结石的次要影响。在第45天，300和1,000 mg/kg/天剂量下的雄性（分别为1和2）和雌性（分别为3和2）尿液中观察到异常晶体（未识别）。在研究结束时，300 mg/kg/天和1,000 mg/kg/天剂量下的雌性也观察到尿结石。在1,000 mg/kg/天剂量组中有一只雌性和在300 mg/kg/天剂量组中有一只雌性观察到膀胱出血、溃疡、炎症和/或粘膜上皮细胞增生。两个1,000 mg/kg/天剂量的雄性也显示出与治疗相关的影响。一只高剂量雄性因尿路结石及其并发症（包括肾小球肾炎、肾小管上皮细胞变性、肾盂化脓性炎症、动脉炎/周围动脉炎、充血、小管蛋白积聚和纤维蛋白在囊周区域的沉积）而被牺牲。膀胱也观察到出血、侵蚀和溃疡，伴有急性炎症和肌层的变性。输尿管损伤与周围组织的炎症、水肿和出血有关。尿道发生炎症和上皮坏死。前列腺腺体观察到出血、急性炎症和血管炎/周围血管炎；这些病变与治疗的关系尚不清楚。研究者认为，这只雄性胸腺淋巴细胞的坏死可能是由于压力后肾上腺皮质激素的释放。第二只雄性犬出现膀胱急性炎症、侵蚀/溃疡和水肿的病变。在接受Sulfosulfuron给药的临床症状、体重/体重增加、食物消耗、眼科结果或血液学和临床化学参数方面没有差异。基于雌性动物膀胱病变和尿结石形成后的异常尿晶体的系统毒性LOEL为300 mg/kg/天。系统毒性的NOEL为100 mg/kg/天。

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a subchronic toxicity study, Sulfosulfuron (98.4% a.i.) was administered to 50 beagle dogs (5 Males/5 Females/dose) by gelatin capsule at dose levels of (0, 30, 100, 300 and 1,000 mg/kg/day) for 90 days. Controls received empty gelatin capsules. Sulfosulfuron's toxic effects were expressed primarily in the urinary tract and appeared to be secondary to formation of urinary calculi at 300 and 1000 mg/kg/day. Abnormal crystals (unidentified) were observed in the urine at day 45 at 300 and 1,000 mg/kg/day (males, 1 and 2, respectively; females, 3 and 2, respectively) and in females at study termination (3 at 300 mg/kg/day and 4 at 1,000 mg/kg/day). Hemorrhage, ulceration, inflammation, and/or mucosal epithelial hyperplasia in the urinary bladder were observed in one female in the 1000 mg/kg/day dose group and one in the 300 mg/kg/day dose group. Two males at 1000 mg/kg/day also showed treatment-related effects. One high dose male was sacrificed due to advanced urolithiasis and associated complications throughout the urinary tract, which included glomerulonephritis, degeneration of renal tubular epithelium, suppurative inflammation of the renal pelvis, arteritis/periarteritis, congestion, tubular protein accumulation and fibrin deposition in the capsular/pericapsular areas. Hemorrhage, erosions and ulcerations with acute inflammation, and degeneration of the tunica muscularis were also observed in the urinary bladder. Inflammation, edema and hemorrhage of periureteral tissue were associated with ureter damage. Inflammation and epithelial necrosis occurred in the urethra. Hemorrhage, acute inflammation and vasculitis/perivasculitis were noted in the prostate gland; the relationship of these lesions to treatment was unclear. The investigators concluded that necrosis of thymic lymphocytes in this male was probably due to release of adrenal cortical hormones subsequent to stress. A second male dog had bladder lesions of acute inflammation, erosions/ulcerations and edema. There were no differences in clinical signs, body weight/weight gain, food consumption, ophthalmologic results or hematology and clinical chemistry parameters related to administration of the Sulfosulfuron. The systemic toxicity LOEL is 300 mg/kg/day, based on lesions in the urinary bladder in females occurring subsequent to urinary crystal ormation/urolithiasis and on abnormal urinary crystals in males and females. The NOEL for systemic toxicity is 100 mg/kg/day.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

广泛吸收，快速排泄；在低剂量时，主要排泄途径是尿液（77-87%），但在高剂量时，则是粪便（55-63%）。

Extensively aborbed and rapidly excreted; at low doses, the major excretion route was the urine (77-87%), but at high doses, the feces (55-63%).

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

在一项代谢研究中，给Sprague-Dawley大鼠口服了放射性标记的Sulfosulfuron（98%的放射性化学纯活性成分）。在预实验中，每性别每组2-3只大鼠被口服给予了(14)C-Pd Sulfosulfuron（放射性标记在嘧啶环的C-5位置）或(14)C-Im Sulfosulfuron（放射性标记在咪唑并吡啶环的C-3位置），剂量为10毫克/千克或1,000毫克/千克。给予Im或Pd同位素的大鼠具有相似的代谢物轮廓；因此，在主要研究中，每性别每组5只大鼠被口服给予了(14)C-Pd、(14)C-Im、(13)C-Im和(12)C- Sulfosulfuron的混合物，单次口服剂量为10毫克/千克或1,000毫克/千克，重复口服剂量为10毫克/千克（连续14天未标记的剂量，随后是1次放射性标记的剂量），或单次静脉注射剂量为10毫克/千克。给药后72小时内，超过90%的放射性被排出（平均总回收率从97%到101%不等）。在所有低剂量组中，77%到87%的放射性通过尿液排出（5-13%通过粪便排出，低剂量单次和重复口服给药以及低剂量静脉给药），而在高剂量时，粪便成为主要的排出途径（雄性63%，雌性55%；尿液排出雄性32%，雌性33%）。胆汁排出现在发生了，如静脉给药组通过粪便排出的情况所示（雄性和雌性分别占给药剂量的9%和5%）。在所有剂量组中，组织中保留的放射性极少（小于0.07%），或尸体中（小于0.17%）。在预实验中，(14)CO2的呼出微不足道（小于0.04%，所有组），因此在主要研究中没有测量。在低剂量时，吸收几乎是完全的（雄性95%，雌性91%），但在高剂量时显著减少（雄性36%，雌性39%）；没有确定这是剂量依赖效应还是剂量-载体效应。

In a metabolism study, radiolabelled Sulfosulfuron (98% radiochemically pure a.i.), was administered to Sprague-Dawley rats. In the pilot study, 2-3 rats/sex/group were administered either (14)C-Pd Sulfosulfuron (radiolabel at the C-5 position of pyrimidine ring) or (14)C-Im Sulfosulfuron (label at the C-3 position of the imidazopyridine ring), each at 10 mg/kg or 1,000 mg/kg, by gavage. Rats dosed with Im or Pd Sulfosulfuron isotopes had similar metabolite profiles; therefore in the main study, 5 rats/sex/group were administered a mixture of (14)C-Pd, (14)C-Im, (13)C-Im and (12)C- Sulfosulfuron at single oral doses of 10 or 1,000 mg/kg, repeated oral doses of 10 mg/kg (14 consecutive daily unlabelled doses, followed by 1 radiolabelled dose), or a single intravenous dose of 10 mg/kg. More than 90% of the administered radioactivity was excreted by 72 hrs post-dosing (mean total recovery ranged from 97% to 101%). Between 77% to 87% of the administered radioactivity was excreted in the urine in all low dose groups (5-13% was excreted in the feces, low single and repeat oral dosing and low iv dosing), whereas feces was the major route of elimination at high dose (63%, males and 55%, females; urinary excretion 32%, males and 33%, females). Biliary excretion appeared to occur, as shown by fecal excretion in the intravenous dose group (9% and 5% of administered dose, males and females). ... In all dose groups, minimal radioactivity was retained in tissues (less than 0.07%) or carcass (less than 0.17%). In the pilot study, expiration of (14)CO2 was insignificant (<0.04% of administered dose, all groups) and therefore not measured in the main study. Absorption was essentially complete at low dose (95%, males and 91%, females) but markedly reduced at the high dose (36%, males and 39%, females); it was not determined whether this was a dose-dependent effect or was due to a dose-vehicle effect.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险品标志：
  N
• 安全说明：
  S60,S61
• 危险类别码：
  R50/53
• WGK Germany：
  2
• 危险品运输编号：
  UN3077 9/PG 3
• RTECS号：
  NJ5808500
• 海关编码：
  2935009011

制备方法与用途

磺酰磺隆简介

磺酰磺隆是近年来新开发的一种磺酰脲类超高效除草剂，其化学名称为1-(4,6-二甲氧嘧啶-2-基)-3-(2-乙基磺酰基咪唑并[1,2-a]吡啶-3-基)磺酰脲。

化学性质

磺酰磺隆纯品为无味的白色固体，熔点在201.1~201.7℃之间。其蒸气压较低，在20℃时为3.1×10^-5 mPa，在25℃时为8.8×10^-5 mPa。根据pH值不同，油/水分配系数(Kow)有所变化：在pH 5、7、9下的值分别为0.73、-0.77和-1.44。相对密度在20℃时为1.5185。

该物质在水中溶解度较低，其溶解度随pH值不同而异，在20℃时的水中溶解度为：pH 5时17.6 mg/L、pH 7时1627 mg/L、pH 9时482 mg/L。有机溶剂中的溶解性较好，其中在丙酮、甲醇、乙酸乙酯、二氯甲烷和二甲苯的溶解度分别为0.71 g/L、0.33 g/L、1.01 g/L、4.35 g/L和0.16 g/L。此外，在20℃下，该物质在庚烷中的溶解度低于0.01 g/L。

磺酰磺隆在温度小于54℃时能稳定存在14天；其水解半衰期随pH值变化而不同：在25℃条件下，pH 4时为7天、pH 5时为48天、pH 7时为168天、pH 9时为156天。pKa值在20℃下为3.51。

作用机制

磺酰磺隆是一种内吸性除草剂，主要通过植物根系和叶面吸收进入植物体内。作为支链氨基酸合成抑制剂，它能阻止必需的氨基酸和异亮氨酸的生物合成过程，从而导致细胞分裂停止、植物生长受阻直至死亡。

用途

磺酰磺隆可用作除草剂，主要用于防治一年生和多年生禾本科杂草及部分阔叶杂草，如野燕麦、早熟禾、蓼属、雀麦等。对于一些难防的杂草，它也有很好的效果。

土壤降解

在土壤中，磺酰磺隆主要通过物理吸附作用与土壤结合，其吸附常数(Kd)在不同类型的土壤中有所差异：江西红壤为3.05、太湖水稻土为1.63和东北黑土为1.15。这些数据表明，在江西红壤中该物质具有中等移动性，在太湖水稻土和东北黑土中的移动性较低，属于可移动级别。

土壤中磺酰磺隆的降解半衰期在14.5至42.5天之间变化；而在土壤表面，其光解半衰期仅为22.6小时。因此，它被认为是难于在土壤表面上进行光解反应的一种农药。

毒性

大鼠急性经口摄入剂量超过5000 mg/kg未见致死作用。兔急性经皮接触的LD50值同样大于5000 mg/kg。该物质对兔子皮肤无刺激，但对眼睛有中度刺激效果。豚鼠实验结果显示其对皮肤没有过敏反应，且无吸入毒性。

动物长期摄入数据表明，在大鼠、狗和小鼠体内的未观察到不良影响剂量分别为24.4~30.4 mg/(kg·d)、100 mg/(kg·d)及93.4～1388.2 mg/(kg·d)。基于此，ADI值被设定为每千克体重摄入0.24毫克。

此外，在进行体外试验中，如甲基化-甲苯咪唑(MES)试验、CHO/HGPRT试验以及人体淋巴细胞和小鼠微核试验均未发现该物质具有遗传毒性。

反应信息

• 作为产物：
  描述：

  {[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]amino}sulfonyl chloride 生成 1-(4,6-二甲氧嘧啶-2-基)-3-(2-乙基磺酰基咪唑[1,2-a]-3-吡啶基磺酰基)脲
  参考文献：
  名称：

  ISIDA, YASUO;OTA, KADZUNARI;NAKAXAMA, MATSUO;JOSIKAVA, XARUTOSI

  摘要：

  DOI：

文献信息

• [EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
  申请人：GILEAD APOLLO LLC

  公开号：WO2017075056A1

  公开（公告）日：2017-05-04

  The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

  本发明提供了化合物I和II，这些化合物可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及它们的组合物和使用方法。
• [EN] 3-[(HYDRAZONO)METHYL]-N-(TETRAZOL-5-YL)-BENZAMIDE AND 3-[(HYDRAZONO)METHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE DERIVATIVES AS HERBICIDES<br/>[FR] DÉRIVÉS DE 3-[(HYDRAZONO))MÉTHYL]-N-(TÉTRAZOL-5-YL)-BENZAMIDE ET DE 3-[(HYDRAZONO)MÉTHYL]-N-(1,3,4-OXADIAZOL-2-YL)-BENZAMIDE UTILISÉS EN TANT QU'HERBICIDES
  申请人：SYNGENTA CROP PROTECTION AG

  公开号：WO2021013969A1

  公开（公告）日：2021-01-28

  The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4, R5 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to methods of controlling weeds using said compositions, and to the use of compounds of Formula (I) as a herbicide.

  本发明涉及以下式（I）的化合物或其农业上可接受的盐，其中Q、R2、R3、R4、R5和R6如本文所述。该发明还涉及包含所述化合物的组合物，使用这些组合物控制杂草的方法，以及将式（I）的化合物用作除草剂的用途。
• [EN] INSECTICIDAL TRIAZINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRIAZINONE INSECTICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2013079350A1

  公开（公告）日：2013-06-06

  Compounds of the formula (I) or (I'), wherein the substituents are as defined in claim 1, are useful as pesticides.

  式(I)或(I')的化合物，其中取代基如权利要求1所定义的那样，可用作杀虫剂。
• [EN] HERBICIDALLY ACTIVE HETEROARYL-S?BSTIT?TED CYCLIC DIONES OR DERIVATIVES THEREOF<br/>[FR] DIONES CYCLIQUES SUBSTITUÉES PAR HÉTÉROARYLE À ACTIVITÉ HERBICIDE OU DÉRIVÉS DE CELLES-CI
  申请人：SYNGENTA LTD

  公开号：WO2011012862A1

  公开（公告）日：2011-02-03

  The invention relates to a compound of formula (I), which is suitable for use as a herbicide wherein G is hydrogen or an agriculturally acceptable metal, sulfonium, ammonium or latentiating group; Q is a unsubstituted or substituted C3-C8 saturated or mono-unsaturated heterocyclyl containing at least one heteroatom selected from O, N and S, or Q is heteroaryl or substituted heteroaryl; m is 1, 2 or 3; and Het is an optionally substituted monocyclic or bicyclic heteroaromatic ring; and wherein the compound is optionally an agronomically acceptable salt thereof.

  该发明涉及一种化合物，其化学式为(I)，适用作为除草剂，其中G为氢或农业可接受的金属、磺酸盐、铵盐或潜伏基团；Q为未取代或取代的含有至少一个来自O、N和S的杂原子的饱和或单不饱和的C3-C8杂环烷基，或Q为杂芳基或取代的杂芳基；m为1、2或3；Het为可选择地取代的单环或双环杂芳环；且该化合物可选择地为其农学上可接受的盐。
• TRIAZOLE ACC INHIBITORS AND USES THEREOF
  申请人：Gilead Apollo, LLC

  公开号：US20170166584A1

  公开（公告）日：2017-06-15

  The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

  本发明提供了三唑化合物，可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及其组合物和使用方法。